Sangamo Therapeutics, Inc.’s SGMO share price has surged by 10.12%, which has investors questioning if this is right time to sell.

Sangamo Therapeutics has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, Vericel has a beta of 1.61, indicating that its share price is 61% ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Now Gilead is spending a further $150 million upfront to access the cutting edge gene-editing technology of another Californian biotech, Sangamo. The ambition for this cancer-focused collaboration ...

RICHMOND, Calif., April 03, 2025--SANGAMO THERAPEUTICS ANNOUNCES CAPSID LICENSE AGREEMENT WITH LILLY TO DELIVER GENOMIC MEDICINES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM RICHMOND, Calif., ...

CPTx GmbH, a pioneer in the therapeutic development and manufacturing of novel medicines built with single-stranded DNA, has ...

Roche’s Genentech is betting on the Flagship Pioneering–founded company’s discovery platform called DECODE to find new ...

STAC-BBB shows widespread neuronal transduction across all cortical regions, according to Sangamo. Sangamo Therapeutics was hit hard by the loss of Pfizer as a partner at the end of last year ...

Addi Maddox chipped in two goals, while Kamryn Hoffman had a goal and two assists in a 6-0 win over Sacred Heart-Griffin. The ...

Pfizer’s Hympavzi (marstacimab) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to ...